Introduction: Alport syndrome is an inherited renal disease characterized by hematuria, renal failure, hearing loss and a lamellated glomerular basement membrane. Patients with Alport syndrome who undergo renal transplantation have been shown to have patient and graft survival rates similar to or better than those of patients with other renal diseases.
Materials and Methods: We performed 35 renal transplants on AS patients(group A)  of overall mean age of 22 ± 7.9 years from 6 deceased and 29 living donors. Two patients underwent second RTx. We compared it with a second group  of  3084 patients of chronic kidney disease(group B) who went under renal transplant at our institute.
Results: Over a follow-up of 1, 3, 5, and 10 years, the mean serum creatinine (mg/dL) were 1.51 ± 0.52, 1.59 ± 0.26, 1.61 ± 0.30, and 1.63 ± 0.32, respectively. Patient survivals at 1, 5, and 10 years were 89.71%, 81.32% and 81.32% with graft survival for all periods of 94.4% in patients with alport syndrome. Where as Patient survivals at 1, 5, and 10 years were 92.1%, 82.9% and 76.6% with graft survival for all periods of 91.1% in patients of other group. Twenty-one percent experienced biopsy-proven acute rejection episodes.
Conclusion: Patients with end-stage kidney disease (ESKD) due to Alports  syndrome have similar patient and graft survival to those with other causes of ESKD. This indicates that early diagnosis and management can lead to favorable outcomes for this patient cohort.